NCT01636037View on ClinicalTrials.gov

Antipsychotic Augmentation With L-Dopa

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

January 31, 2016

Conditions
Schizophrenia
Interventions
DRUG

levodopa/carbidopa (generic version of Sinemet)

Oral levodopa 900mg daily as tolerated.

Trial Locations (1)

M5T 1R8

Centre for Addiction and Mental Health, Toronto

All Listed Sponsors
lead

Centre for Addiction and Mental Health

OTHER

NCT01636037 - Antipsychotic Augmentation With L-Dopa | Biotech Hunter | Biotech Hunter